Completed OBSERVATIONAL NCT00812175

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)

Sponsor: Bayer

Interventions Sorafenib (Nexavar, BAY43-9006)

Updated 7 times since 2017 Last updated: Oct 14, 2016 Started: Jan 31, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Carcinoma, Hepatocellular and is currently completed. Bayer leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Many Locations, Canada , Many Locations, China , Many Locations, Colombia , Many Locations, Croatia , Many Locations, Czechia , Many Locations, Finland , Many Locations, France , Many Locations, Greece , Many Locations, Hong Kong , Many Locations, Hungary and 29 more locations